Hong Ma, MD, MSc, MBA, CARsgen Therapeutics, Shanghai, China, provides his perspectives on advancements in the chimeric antigen receptor (CAR) T-cell field. Developments within the liquid tumor space include novel treatments targeting B-cell maturation antigen (BCMA) receptors and further approvals are expected in the near future. There is currently a great deal of attention being paid toward CAR-T therapies for solid tumors, with early proof-of-concept studies having highlighted their potential. In addition, Dr Ma discusses the current status of research into the development of allogeneic CAR T-cell therapies and the need for the implementation of new technologies to overcome current challenges. This interview took place during the CAR-TCR Summit Europe 2021.